Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

STACKD0E Jul. 21 at 1:01 PM

$CRMT $SILO ✨️

0 · Reply

Stock_Catcher Jul. 21 at 12:55 PM

$SILO Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

0 · Reply

SmartMoneyTradez Jul. 15 at 11:26 PM

$ATPC Hello shorts $SILO

0 · Reply

buywhenhurt Jul. 14 at 3:39 PM

$SILO from $4.45 to $5 was a nice bounce today. Now let’s see if TRNR can bounce next. Back over $3+

0 · Reply

tommycman Jul. 14 at 2:31 PM

$SILO looks ready to go up.. Maybe last chance to buy in at a decent price. MACD an STOCH both flipped. Hoping for $5+ shortly..

0 · Reply

Agguie Jul. 14 at 1:49 PM

$SILO nope looks like a dud at the moment

0 · Reply

buywhenhurt Jul. 14 at 1:47 PM

$SILO nice pullback spot here for a bounce today

0 · Reply

Agguie Jul. 14 at 1:15 PM

$SILO maybe some traction at opening ??? Volume doesn’t look enough to dilute into but I may be wrong it is a lower float

0 · Reply

AIBulll Jul. 14 at 1:12 PM

$SILO popping after QwikAgents got into $AMD's AI Developer Program. Cloud credits, tools, training, and access to AMD’s dev network — real setup for faster AI work in the biopharma pipeline. Nice catalyst, and the market is clearly treating it that way.

0 · Reply

Trader1141 Jul. 14 at 1:08 PM

$SILO did they announce offering closed?

0 · Reply

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

2026-07-14T13:20:49.000Z - 7 days ago

Silo Pharma subsidiary QwikAgents joins AMD AI program

AMD

Jul 14, 2026, 8:55 AM EDT - 7 days ago

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

2026-07-10T12:16:17.000Z - 11 days ago

Silo Pharma prices $11.7M at-the-market offering at $6.45 per share

Jul 10, 2026, 8:00 AM EDT - 11 days ago

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jul 7, 2026, 8:11 AM EDT - 14 days ago

Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program

2026-06-29T20:50:29.000Z - 21 days ago

Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery

Jun 29, 2026, 4:15 PM EDT - 22 days ago

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

2026-06-23T15:29:15.000Z - 4 weeks ago

Silo Pharma reports positive stability data for stress treatment SPC-15

Jun 23, 2026, 8:17 AM EDT - 4 weeks ago

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial

2026-06-18T12:33:09.000Z - 4 weeks ago

Silo Pharma regains compliance with Nasdaq min bid price requirement

Jun 18, 2026, 8:12 AM EDT - 4 weeks ago

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-06-02T23:50:11.000Z - 6 weeks ago

Silo Pharma Inc trading halted, news pending

2026-05-07T18:37:18.000Z - 2 months ago

Silo Pharma files provisional patent for ibogaine-based therapeutics

May 7, 2026, 8:05 AM EDT - 2 months ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Apr 29, 2026, 9:08 AM EDT - 2 months ago

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

2026-04-22T21:10:17.000Z - 3 months ago

Silo Pharma expands into AI technology with Qwikagents asset purchase

Apr 22, 2026, 4:15 PM EDT - 3 months ago

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

2026-04-06T20:20:47.000Z - 3 months ago

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

Apr 6, 2026, 4:15 PM EDT - 3 months ago

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

2026-02-23T21:38:21.000Z - 5 months ago

Silo Pharma announces $1M share repurchase program

Feb 23, 2026, 4:15 PM EST - 5 months ago

Silo Pharma Announces Share Buyback Program

2026-02-18T13:35:47.000Z - 5 months ago

Silo Pharma receives Notice of Allowance in Japan for SPC-15

Feb 18, 2026, 8:28 AM EST - 5 months ago

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

2025-12-30T13:35:34.000Z - 7 months ago

Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15

Dec 30, 2025, 8:05 AM EST - 7 months ago

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

2025-11-17T13:11:11.000Z - 8 months ago

Silo Pharma partners with Allucent for planned FDA IND application for SPC-15

Nov 17, 2025, 8:05 AM EST - 8 months ago

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

2025-10-29T12:30:37.000Z - 9 months ago

Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments

Oct 29, 2025, 8:25 AM EDT - 9 months ago

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Oct 23, 2025, 8:45 AM EDT - 9 months ago

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Oct 8, 2025, 8:45 AM EDT - 10 months ago

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

Oct 6, 2025, 8:10 AM EDT - 10 months ago

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Oct 1, 2025, 4:20 PM EDT - 10 months ago

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 30, 2025, 8:02 AM EDT - 10 months ago

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 16, 2025, 8:11 AM EDT - 11 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Sep 9, 2025, 9:10 AM EDT - 11 months ago

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Sep 3, 2025, 8:25 AM EDT - 11 months ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Aug 21, 2025, 2:00 PM EDT - 11 months ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 19, 2025, 8:05 AM EDT - 1 year ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 5, 2025, 8:32 AM EDT - 1 year ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Jul 16, 2025, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 1 year ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 1 year ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 1 year ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 1 year ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 1 year ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 1 year ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 1 year ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 1 year ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 1 year ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 18, 2024, 8:40 AM EST - 1 year ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Oct 31, 2024, 8:35 AM EDT - 1 year ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

STACKD0E Jul. 21 at 1:01 PM

$CRMT $SILO ✨️

0 · Reply

Stock_Catcher Jul. 21 at 12:55 PM

$SILO Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

0 · Reply

SmartMoneyTradez Jul. 15 at 11:26 PM

$ATPC Hello shorts $SILO

0 · Reply

buywhenhurt Jul. 14 at 3:39 PM

$SILO from $4.45 to $5 was a nice bounce today. Now let’s see if TRNR can bounce next. Back over $3+

0 · Reply

tommycman Jul. 14 at 2:31 PM

$SILO looks ready to go up.. Maybe last chance to buy in at a decent price. MACD an STOCH both flipped. Hoping for $5+ shortly..

0 · Reply

Agguie Jul. 14 at 1:49 PM

$SILO nope looks like a dud at the moment

0 · Reply

buywhenhurt Jul. 14 at 1:47 PM

$SILO nice pullback spot here for a bounce today

0 · Reply

Agguie Jul. 14 at 1:15 PM

$SILO maybe some traction at opening ??? Volume doesn’t look enough to dilute into but I may be wrong it is a lower float

0 · Reply

AIBulll Jul. 14 at 1:12 PM

0 · Reply

Trader1141 Jul. 14 at 1:08 PM

$SILO did they announce offering closed?

0 · Reply

EZ_Money11 Jul. 14 at 12:59 PM

$SILO 🗞️

0 · Reply

premarketmaker Jul. 14 at 12:58 PM

$SILO nibble here $6.40 1m float with catalyst

0 · Reply

Stock_Catcher Jul. 14 at 12:55 PM

$SILO Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

0 · Reply

KiserSose Jul. 11 at 6:53 AM

$SILO Since the stock has been in the 5s and 6 dollar range. I would suspect it will fall into the 4 to 5 dollar range..with the coming dilution..

0 · Reply

flychicken1991 Jul. 10 at 12:54 PM

$SILO Negative (96%): SILO’s stock price is pressured by immediate ownership dilution and the prospect of additional shares entering the market through warrant exercises, which can cap rebounds and force a lower per-share valuation. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/a8bcd81df2222bf4?utm_source=stocktwits&utm_medium=story_url

0 · Reply